 This is a pilot study evaluating the feasibility of a cognitive-behavioral smoking cessation plus Varenicline program, designed specifically for early stage lung cancer patients and patients with a potential lung cancer diagnosis pre and post-surgery. The study population will be approximately 80 smokers who have upcoming lung resection surgery scheduled at Massachusetts General Hospital MGH in Boston. A patient will be considered eligible for the intervention or control group if he or she 1 is scheduled for a lung resection surgery with either a lung cancer diagnosis or a potential lung cancer diagnosis, and 2 had a cigarette in the past 2 weeks, 3 is willing to make a pre-surgical quit attempt. Patients will be excluded from the control group if they are 1 non-English speaking, 2 determined medically ineligible by their surgeononcologist, 3 suffering from psychosis or dementia 4 is currently on Varenicline has been on Varenicline for more than 3 weeks, or 5 is otherwise unable to participate in the intervention. Patients will be excluded from the intervention group if they are 1 non-English speaking, 2 determined medically ineligible by their surgeon, 3 suffering from psychosis or dementia 4 have been taking Varenicline for longer than three weeks 5 have been taking Bupropion for smoking cessation purposes for more than three weeks, 6 is otherwise unable to participate in the intervention. 